- Patients with recurrent disease. Greater than 12 weeks elapsed from surgery to enrollment. Prior pelvic or abdominal radiation therapy. Known hypersensitivity to any component of study treatment. Active pregnancy or lactation. Treatment for prior malignancy in the last 3 years.